Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Micardis®

Study type: Observational

Funder types: Industry

Identifiers

NCT02242331

502.386

Details and patient eligibility

About

This post-marketing surveillance study is designed to supplement under conditions of normal clinical practice data on safety, tolerability and efficacy of Micardis® collected in clinical studies with special emphasis on the control of blood pressure in the morning before intake of the next antihypertensive drug

Enrollment: 19,805 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Essential hypertension
• At least 18 years of age

Exclusion criteria

• NA

Trial design

19,805 participants in 1 patient group

essential hypertension patients

Treatment:

Drug: Micardis®